CS
KURA icon

Candriam SCA’s Kura Oncology KURA Stock Holding History

Candriam SCA’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-422,652
Closed -$2.79M – 702
2025
Q1 		$2.79M Hold
422,652
– – 0.02% 441
2024
Q4 		$3.68M Sell
422,652
-483,830
-53% -$6.96M 0.02% 401
2024
Q3 		$17.7M Hold
906,482
– – 0.1% 198
2024
Q2 		$18.7M Buy
906,482
+255,065
+39% +$5.24M 0.11% 184
2024
Q1 		$13.9M Buy
651,417
+110,000
+20% +$2.14M 0.09% 214
2023
Q4 		$7.79M Sell
541,417
-150,005
-22% -$1.48M 0.05% 286
2023
Q3 		$6.31M Hold
691,422
– – 0.04% 289
2023
Q2 		$7.32M Sell
691,422
-122,942
-15% -$1.45M 0.05% 287
2023
Q1 		$9.17M Hold
814,364
– – 0.06% 270
2022
Q4 		$10.1M Buy
814,364
+118,789
+17% +$1.73M 0.07% 275
2022
Q3 		$9.5M Buy
695,575
+257,260
+59% +$3.97M 0.07% 283
2022
Q2 		$8.03M Hold
438,315
– – 0.07% 261
2022
Q1 		$7.05M Sell
438,315
-469,118
-52% -$6.77M 0.05% 301
2021
Q4 		$12.7M Sell
907,433
-38,924
-4% -$631K 0.08% 230
2021
Q3 		$17.7M Hold
946,357
– – 0.12% 194
2021
Q2 		$19.7M Buy
946,357
+17,080
+2% +$424K 0.14% 178
2021
Q1 		$29.2M Sell
929,277
-5
-0% -$158 0.24% 108
2020
Q4 		$30.4M Buy
929,282
+390,086
+72% +$13.7M 0.24% 108
2020
Q3 		$16.5M Buy
539,196
+299,492
+125% +$6.61M 0.16% 157
2020
Q2 		$3.91M Buy
+239,704
New +$3.46M 0.04% 384
2019
Q4 		– Sell
-138,100
Closed -$2.1M – 799
2019
Q3 		$2.1M Sell
138,100
-224,000
-62% -$3.99M 0.03% 476
2019
Q2 		$7.1M Sell
362,100
-33,900
-9% -$563K 0.09% 255
2019
Q1 		$6.57M Buy
396,000
+30,000
+8% +$462K 0.08% 266
2018
Q4 		$5.14M Hold
366,000
– – 0.08% 279
2018
Q3 		$6.41M Sell
366,000
-16,000
-4% -$307K 0.09% 272
2018
Q2 		$6.95M Sell
382,000
-3,000
-0.8% -$50.8K 0.11% 233
2018
Q1 		$7.22M Sell
385,000
-130,000
-25% -$2.53M 0.12% 212
2017
Q4 		$7.88M Sell
515,000
-25,000
-5% -$368K 0.14% 189
2017
Q3 		$8.07M Buy
+540,000
New +$5.07M 0.14% 178

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Candriam SCA's KURA Position: Q2 2025 in Review

Candriam SCA sold out of Kura Oncology (KURA) in Q2 2025, closing a stake of 422,652 shares — an estimated $2.79M sold.

Candriam SCA first reported a position in KURA in Q3 2017 and held it in 29 quarters. The position peaked at $30.4M in Q4 2020. 182 funds tracked by Wall St. Rank hold KURA as of Q2 2025.

  • Candriam SCA reported no remaining Kura Oncology position as of Q2 2025 after selling out during the quarter.
  • Candriam SCA sold 422,652 Kura Oncology shares in Q2 2025, an estimated $2.79M.
  • Candriam SCA first reported a position in Kura Oncology in Q3 2017 and held it in 29 quarters.
  • Candriam SCA's Kura Oncology position peaked at $30.4M in Q4 2020.
  • 182 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2025.

Based on Candriam SCA's 13F filing for Q2 2025, filed 8 Aug 2025.